chronic obstructive pulmonary disease

Showing 11 posts of 11 posts found.

NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears

July 10, 2018
Manufacturing and Production, Medical Communications, Research and Development COPD, NICE, antimicrobial resistance, chronic obstructive pulmonary disease, pharma

NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when …

NICE turns down AZ’s chronic obstructive pulmonary disease drug

February 13, 2017
Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease

AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …


GSK 18 months ahead of the game with three-drug inhaler

November 21, 2016
Medical Communications, Sales and Marketing GSK, Innoviva, chronic obstructive pulmonary disease

GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary …


GSK announce positive results for chronic obstructive pulmonary disease treatment

September 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing GlaxoSmithKline, Innoviva, Revlar Ellipta, chronic obstructive pulmonary disease

GlaxoSmithKline and its partner Innoviva have announced that its Relvar Ellipta achieved positive results in its COPD Salford lung study …

Advair image

Europe must prepare for COPD ‘timebomb’

November 19, 2014
Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease

Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …

FDA delays decision on Novartis’ COPD drug

March 23, 2011
Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

Novartis’ COPD drug recommended for FDA approval

March 10, 2011
Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol

Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …

Forest’s COPD drug approved in US

March 3, 2011
Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast

Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …

Blog footer

Digital Pharma: Pfizer and Boehringer’s online COPD awareness

November 12, 2010
Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease

Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …

Pfizer and Boehringer's COPD campaign website

Pfizer and Boehringer pilot COPD campaign

November 9, 2010
Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema

Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …

Almirall and Forest’s phase III COPD drug misses goal

November 3, 2010
Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease

Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …

Latest content